Lilly’s weight loss drug reduces diabetes risk in overweight patients
Eli Lilly’s weight-loss drug Zepbound dramatically reduces the risk of developing type 2 diabetes in overweight or obese pre-diabetic adults after three years of weekly injections, the drug’s maker said Tuesday.
ENTRADAS POPULARES
UK sets new climate target for 2035
noviembre 13, 2024
Children go back to school after Valencia floods
noviembre 13, 2024
Researchers document huge decline in African elephants
noviembre 13, 2024
Mission: Impossible 8 title revealed
noviembre 13, 2024
TRANSMISIÓN EN VIVO